RxDoctor Payments Data

Abdullahi Oseni, MD

Interventional Cardiology · Louisville, KYNPI 1033478227

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (41.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Shockwave Medical, Inc at 52.8% of the total. Reporting peaked in 2023 at $9,951 and has fallen 93.6% since, to $638 in 2025.

$15,920in general payments, 2019–2025

Across 133 payments — averaging $119.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$8K
  • Boston Scientific$2K
  • Ancora Heart, Inc.$1K
  • Inari Medical, Inc.$1K
  • Abiomed$1K
  • Penumbra, Inc.$421
  • plus $2K from 11 others
$81,334in research payments, 2019–2025

Across 9 payments — averaging $9037.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shockwave Medical, Inc$81K

What the payments were for

  • Speaking & faculty fees$6,60041%
  • Grants$2021%
  • Travel & lodging$3,32721%
  • Food & beverage$5,79136%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,920 in reported general payments places this provider in the 65th percentile of 129 interventional cardiology providers in Kentucky.

See all interventional cardiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$174,447
Medicare patients
1,253
Services billed
2,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$55,784
BrilintaTicagrelor33$18,661
Repatha SureclickEvolocumab16$15,057
Prasugrel Hcl45$4,280
Atorvastatin Calcium181$1,001
Ranolazine ErRanolazine19$882
Metoprolol Succinate68$697
Isosorbide Mononitrate ErIsosorbide Mononitrate59$390
Rosuvastatin Calcium45$327
Bisoprolol Fumarate11$274
ClopidogrelClopidogrel Bisulfate40$267
Warfarin Sodium27$261
Carvedilol19$234
Furosemide41$184
Amlodipine Besylate34$182

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →